
Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.
Frontline Treatment Options for Hodgkin's Lymphoma
A 32-Year-Old Man with Stage IV Hodgkin's Lymphoma
